INTRODUCTION
Introduction
Tuberculosis
Chronic
infectious
disease
Mycobacterium
tuberculosis
Other
Mycobacterium
complex
Tuberculosis
Major cause of
morbidity and mortality
1/3 world have been
infected
Introduction
2010
8.8 million
Incident Cases
Deaths caused by TB
1.1 million
HIV-negative
0.35 million
HIV-associated TB
MDRTB
HIV
TB
Control
Program
XDRTB
Absence of
treatment for
MDR-TB
Major
challenge for
TB control
program
MDR - TB
650.000
New
Case
5% of all TB
Death
Case
fatality
rate
150.000
30 / 100
individuals
HIV
XDRTB
HIV
Balanced
deadlier
combination
MDRTB
Relationship?
METHODS
Systematic
Review
MetaAnalysis
Computerized
Hand searching
Medline/ Pubmed
Google Scholar
HINARI
Study Selection
Observational Studies
Crosssectional
Surveillance
Case
control
Cohort
Eligibility Criteria
Drug susceptibility to Rifampicin
and Isoniazid of MTB
Stratified by HIV status
Exclusion Criteria
Extrapulmonary
TB
Mycobacterium
other than TB
HIV is not
considered as
risk factor
Children <15
years old
Meta-analysis or
systematic
review
Duplicate
publication
Only abstract
Case control
Data Synthesis
Drug resistance
Resistance to 1 or more first line drug
Mono resistance
One of the 5 first-line drugs
Secondary Resistance
Acquired resistance during the treatment
RESULTS
DISCUSSION
24 %
40%
Not satistically significant
HIV
Significant
with primary
Not associated
with secondary
Biological Mechanism
Faster progress of
infection
Drugs mal-absorbtion
Treatment Failure
CONCLUSION
Risk of MDR TB
People with HIV infection
Implication?
Early case
detection
Qualityassured
bacteriology
Reduce risk
of spread of
MDR-TB
Provide
standardized
treatment
Good
infection
control
Problem
from MDR-TB.
Intervention
No intervention.
Comparison
No comparison
Outcome
CRITICAL APPRAISAL
Yes
Cant
tell
No
Yes
included?
tell
Look for
Cant
No
displayed
confidence intervals?
...thank you